0
0
SILVER SPRING, MD — The U.S. Food and Drug Administration (FDA) has announced that Inventia Healthcare Limited has initiated a nationwide, voluntary recall of 11,460 bottles of chlorthalidone tablets, USP, 25 mg. The recall, finalized in June 2026, was triggered after routine laboratory testing revealed that the product failed to meet standard dissolution specifications. Classified by the FDA as a Class II recall, federal officials warn that improper dissolution could reduce the drug’s effectiveness, potentially leading to underdosing and compromised blood pressure control for patients relying on the medication.
Key Findings and Product Details
The voluntary recall impacts specific batches of chlorthalidone 25 mg distributed across the United States by Rising Pharma Holdings. The recall is strictly limited to two specific bottle sizes, both carrying an expiration date of April 2027:
-
100-tablet bottles: Batch number RISA24001, NDC 64980-599-01
-
1,000-tablet bottles: Batch number RISB24002, NDC 64980-599-10
According to regulatory logs, the manufacturer, Mumbai-based Inventia Healthcare Limited, identified the quality control failure during post-market stability testing.
The FDA’s Class II classification signifies a situation in which exposure to the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health effects is remote.
Why Dissolution Matters: A Plain-Language Explanation
To understand why this recall is necessary, it helps to understand how oral medications work inside the body. Before a medicine can enter the bloodstream and perform its therapeutic job, the tablet must break down and dissolve in the stomach or intestines. This process is known as dissolution.
In pharmaceutical manufacturing, dissolution testing mimics the human digestive tract in a laboratory setting to ensure that a tablet releases its active ingredient at a precise, predictable rate. When a batch fails this test, it means the tablets may dissolve too slowly or incompletely.
For individuals taking chlorthalidone—a long-acting, thiazide-like diuretic frequently prescribed to manage hypertension (high blood pressure) and reduce fluid retention—poor dissolution means the body may absorb less than the intended 25 mg dose. This insufficient absorption can quietly undermine blood pressure management, leaving patients vulnerable to the silent risks of uncontrolled hypertension.
Independent Expert Perspective
Medical experts emphasize that while the recall requires prompt attention, it represents a breakdown in manufacturing consistency rather than a dangerous chemical contamination.
“A dissolution failure is primarily a manufacturing or formulation problem rather than a new safety signal, but it can meaningfully reduce the efficacy of the medication,” notes Dr. Meera Patel, a clinical pharmacologist at XYZ Hospital who was not involved in the manufacturing or the recall process. “If the drug does not dissolve properly, patients simply are not getting the dose their doctor intended.”
Dr. Patel urges patients not to panic but to take systematic action. “People who believe they may have one of the affected bottles should contact their pharmacist or prescriber immediately to verify lot numbers and secure a reliable replacement or an alternative therapy.”
Context and Regulatory Background
Quality control interventions for cardiovascular medications are not uncommon. Over the last decade, the FDA has overseen several high-profile recalls of antihypertensive drugs. However, public health officials note that this specific recall differs significantly from past incidents.
Many recent historical recalls—such as those involving certain angiotensin II receptor blockers (ARBs) like valsartan—were driven by the discovery of trace chemical impurities like nitrosamines, which are classified as potential carcinogens. In contrast, this chlorthalidone recall is entirely focused on physical drug performance. There is no indication that these tablets contain toxic contaminants or foreign impurities; rather, the mechanical behavior of the tablet itself failed to meet standards.
What Patients Should Do Now
If you or a loved one takes chlorthalidone, health authorities recommend taking the following practical steps:
-
Check Your Bottle: Examine the label of your medication bottle for the specific NDC numbers and lot codes (RISA24001 for 100-count bottles or RISB24002 for 1,000-count bottles) and the April 2027 expiration date. If the numbers do not match, your medication is not part of this recall.
-
Do Not Abruptly Stop Medication: Medical professionals strongly advise against stopping your blood pressure medication suddenly. Sudden discontinuation of an antihypertensive can cause a rapid rebound in blood pressure, significantly increasing the short-term risk of severe cardiovascular events like heart attacks or strokes.
-
Consult Your Healthcare Team: If your bottle matches the recalled lots, contact your pharmacy or prescribing physician. Pharmacies can verify the stock, guide you on return or disposal procedures, and provide an unaffected replacement batch or alternative prescription to ensure your treatment remains uninterrupted.
-
Report Adverse Events: Any unusual symptoms or drop-offs in blood pressure control can be reported to the FDA’s MedWatch Adverse Event Reporting program online or by phone.
Public Health Implications and Limitations
From a broader public health perspective, the scope of this recall is relatively contained. With 11,460 bottles affected, the recall represents a small fraction of the millions of antihypertensive prescriptions filled across the United States every year. Consequently, widespread systemic shortages of chlorthalidone are not anticipated, though minor, localized supply disruptions could occur at specific pharmacies relying heavily on the affected distributor.
It is important to highlight that no confirmed patient harm or adverse events have been reported to date in connection with these specific batches. The recall is a precautionary, preventive measure designed to mitigate the risk of therapeutic failure before patients experience clinical consequences.
Currently, the exact root cause of the dissolution failure—whether stemming from a specific production run variation, a change in inactive binders (excipients), or environmental storage factors—has not been publicly disclosed. Investigations by Inventia Healthcare Limited and regulatory agencies remain ongoing.
Guidance for Clinicians and Pharmacists
Healthcare providers play a vital role in maintaining continuity of care during product recalls.
Pharmacies should immediately audit their active inventory, quarantine any remaining stock from batches RISA24001 and RISB24002, and proactively review dispensing records to notify patients who may have received the affected product.
Clinicians are encouraged to review patient medication lists during upcoming routine or telehealth appointments. Prioritizing outreach to high-risk individuals—such as those with a history of resistant hypertension, brittle fluid balance, or concurrent chronic kidney disease—ensures that transitions to verified, unaffected batches occur seamlessly and safely.
References
- https://www.wral.com/lifestyles/health/11000-bottles-blood-pressure-medicine-recall-june-2026/
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
